VBI Vaccines Stock Is Trading Higher On Encouraging Data From COVID-19 Vaccine Candidate Trial

  • VBI Vaccines Inc VBIV has announced positive Phase 1 data from its Phase 1/2 trial evaluating its enveloped virus-like particle (eVLP) COVID-19 vaccine candidate VBI-2902a.
  • VBI-2902a was well-tolerated, with no safety signals observed.
  • After two doses, VBI-2902a induced neutralization titers in 100% of participants, with 4.3x higher geometric mean titer (GMT) than that of the convalescent serum panel (n=25).
  • After two doses, VBI-2902a also induced antibody binding titers in 100% of participants, with a GMT of 4,047 units/mL, 5.0x the GMT of the convalescent serum panel.
  • Data from this study also support the assessment of a one-dose booster regimen in seropositive individuals.
  • The company will initiate the next phase of the ongoing adaptive Phase 1/2 study expected in Q3 2021 with the VBI-2905a candidate directed against the COVID-19 Beta (B.1.351) variant of concern.
  • H1 2022: Expected initiation of the first study of VBI's multivalent candidate, designed to increase the breadth of protection against COVID-19.
  • VBI Vaccines will host a conference call and webcast today at 8:30 AM ET. 
  • Price Action: VBIV shares are up 4.61% at $4.20 during the premarket session on the last check Tuesday.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: BiotechNewsPenny StocksHealth CareSmall CapGeneralBriefsCOVID-19 Vaccine
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!